<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231114</url>
  </required_header>
  <id_info>
    <org_study_id>04-02</org_study_id>
    <nct_id>NCT00231114</nct_id>
  </id_info>
  <brief_title>Asthma Intervention Research 2 (AIR2) Trial</brief_title>
  <official_title>Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized, double blind, sham-controlled study is to demonstrate the
      safety and effectiveness of the Alair System in a population of subjects with severe asthma
      who are still symptomatic despite being managed on conventional therapy of high doses of
      inhaled corticosteroids and long-acting β2-agonists.

      The primary efficacy endpoint will be the difference between Study groups in the change in
      Asthma Quality of Life Questionnaire (AQLQ) score from Baseline and the average score from
      the 6-, 9-, and 12-month follow-up visits.

      All other outcome measures assessed at 12 months post-treatment.

      This will be a multicenter, randomized, double-blind, sham-controlled study comparing the
      effects of treatment with the Alair System to conventional therapy of inhaled corticosteroids
      (ICS) and long-acting β2-agonists (LABA).

      A Bayesian adaptive approach to sample size selection is used with a randomization scheme of
      2:1 (two Alair Group Subjects for every one Control Group Subject).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the &quot;Integrated AQLQ Score.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Symptom-Free Days (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Puffs of Rescue Medication Used (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Days Rescue Medication Used (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ) Score (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient's FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (amPEF) (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Severe Exacerbations Requiring Systemic Corticosteroids</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Rate of occurrence of worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Subjects With Severe Exacerbations Requiring Systemic Corticosteroids</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Percent of subjects experiencing worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Days Lost From Work/School/Other Activities Due to Asthma</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Unscheduled Physician Office Visits for Respiratory Symptoms</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Emergency Room Visits for Respiratory Symptoms</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalizations for Respiratory Symptoms</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">297</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Alair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of airways with the Alair System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment of airways</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alair System</intervention_name>
    <description>Treatment of airways with the Alair System</description>
    <arm_group_label>Alair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alair System</intervention_name>
    <description>Sham treatment of airways with the Alair System</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an adult between the ages of 18 to 65 years.

          -  Subject has asthma and is taking regular maintenance medication that includes Inhaled
             corticosteroid (ICS) AND long acting ß2-agonist (LABA).

          -  Subject has a Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of
             greater than or equal to 60% of predicted after medication stabilization during the
             Baseline Period.

          -  Subject has a PC20 &lt; 8 mg/ml per methacholine inhalation test using standardized
             methods. PC20 is a provocative concentration of Provocholine® (a brand of methacholine
             chloride) resulting in a drop of FEV1 of 20% or more from Baseline.

          -  Subject has at least two days of asthma symptoms during the 4-weeks of the Baseline
             Diary Period.

          -  Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack
             years total smoking history).

        Exclusion Criteria:

          -  Subject has a Post-bronchodilator FEV1 of less than 65%.

          -  Subject has 3 or more hospitalizations for exacerbations of asthma in the previous
             year; OR a history of life-threatening asthma, defined by past intubations for asthma,
             or ICU admission for asthma within the prior 24 months.

          -  Subject has a history of recurrent lower respiratory tract infections requiring
             antibiotics (more than 3 in the past 12 months).

          -  Subject has a history of recurrent oral steroid use for asthma (4 or more pulses of
             oral steroids in the past 12 months).

          -  Subject has a known sensitivity to medications required to perform bronchoscopy (such
             as lidocaine, atropine and benzodiazepines).

          -  Subject has known systemic hypersensitivity or contraindication to Methacholine
             chloride or other parasympathomimetic agents.

          -  Subject has other medical criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narinder S Shargill, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Asthmatx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Adult Asthma and Allergy Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peoria Pulmonary Associates, Ltd.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veritas Clinical Specialties</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Specialty Center, Lung and Sleep Health</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Catholic Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennyslvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, PC - Baptist Hospitals of East Tennesse</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Hospital Center</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205-3698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>CEP 90610-00</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa de Miscericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>CEP 90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clementino Fraga Filho</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade da Medicina do ABC</name>
      <address>
        <city>Sao Paulo</city>
        <zip>CEP 09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Firestone Institute of Respiratory Health, St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Laval, Centre de Pneumologie</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4GS</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitets Hospital, University of Odense</name>
      <address>
        <city>Odense</city>
        <zip>5000 Odense C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospital, University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield General Hospital, Univ. Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea &amp; Westminster Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Lung Research Center, Univ. of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT01350414?term=PAS1&amp;rank=1</url>
    <description>The AIR2 Extension Study (PAS1) contains the Year 2 to Year 5 Study Results.</description>
  </link>
  <reference>
    <citation>Pavord ID, Thomson NC, Niven RM, Corris PA, Chung KF, Cox G, Armstrong B, Shargill NS, Laviolette M; Research in Severe Asthma Trial Study Group. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol. 2013 Nov;111(5):402-7. doi: 10.1016/j.anai.2013.05.002. Epub 2013 Jun 13.</citation>
    <PMID>24125149</PMID>
  </reference>
  <results_reference>
    <citation>Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Hales JB, McEvoy C, Slebos DJ, Holmes M, Phillips MJ, Erzurum SC, Hanania NA, Sumino K, Kraft M, Cox G, Sterman DH, Hogarth K, Kline JN, Mansur AH, Louie BE, Leeds WM, Barbers RG, Austin JH, Shargill NS, Quiring J, Armstrong B, Castro M; Asthma Intervention Research 2 Trial Study Group. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec;132(6):1295-302. doi: 10.1016/j.jaci.2013.08.009. Epub 2013 Aug 30.</citation>
    <PMID>23998657</PMID>
  </results_reference>
  <results_reference>
    <citation>Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24. doi: 10.1164/rccm.200903-0354OC. Epub 2009 Oct 8.</citation>
    <PMID>19815809</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <results_first_submitted>August 31, 2010</results_first_submitted>
  <results_first_submitted_qc>October 28, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2010</results_first_posted>
  <disposition_first_submitted>February 10, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 12, 2010</disposition_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alair</title>
          <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death: Motor Vehicle Accident</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alair</title>
          <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="190"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="288"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="11.89"/>
                    <measurement group_id="B2" value="40.6" spread="11.85"/>
                    <measurement group_id="B3" value="40.65" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)</title>
        <description>Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the “Integrated AQLQ Score.&quot;</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)</title>
          <description>Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the “Integrated AQLQ Score.&quot;</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="1.10"/>
                    <measurement group_id="O2" value="1.16" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Symptom-Free Days (Change From Baseline)</title>
        <description>Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Symptom-Free Days (Change From Baseline)</title>
          <description>Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="36.16"/>
                    <measurement group_id="O2" value="21.0" spread="35.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Symptom Score (Change From Baseline)</title>
        <description>Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Symptom Score (Change From Baseline)</title>
          <description>Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.32"/>
                    <measurement group_id="O2" value="-1.6" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Puffs of Rescue Medication Used (Change From Baseline)</title>
        <description>Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Puffs of Rescue Medication Used (Change From Baseline)</title>
          <description>Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Puffs/7 Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="16.67"/>
                    <measurement group_id="O2" value="-4.3" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Days Rescue Medication Used (Change From Baseline)</title>
        <description>Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Rescue Medication Used (Change From Baseline)</title>
          <description>Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="33.51"/>
                    <measurement group_id="O2" value="-22.0" spread="36.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ) Score (Change From Baseline)</title>
        <description>Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient’s FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient’s asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ) Score (Change From Baseline)</title>
          <description>Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient’s FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient’s asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.95"/>
                    <measurement group_id="O2" value="-0.77" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (amPEF) (Change From Baseline)</title>
        <description>Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (amPEF) (Change From Baseline)</title>
          <description>Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>L/Min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="49.78"/>
                    <measurement group_id="O2" value="22.3" spread="51.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)</title>
        <description>Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)</title>
          <description>Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="14.71"/>
                    <measurement group_id="O2" value="-0.1" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)</title>
        <description>Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)</title>
          <description>Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="10.74"/>
                    <measurement group_id="O2" value="-2.4" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Severe Exacerbations Requiring Systemic Corticosteroids</title>
        <description>Rate of occurrence of worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe Exacerbations Requiring Systemic Corticosteroids</title>
          <description>Rate of occurrence of worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Events/Subject/Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.07"/>
                    <measurement group_id="O2" value="0.70" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects With Severe Exacerbations Requiring Systemic Corticosteroids</title>
        <description>Percent of subjects experiencing worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Severe Exacerbations Requiring Systemic Corticosteroids</title>
          <description>Percent of subjects experiencing worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.</description>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Percent of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Days Lost From Work/School/Other Activities Due to Asthma</title>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Lost From Work/School/Other Activities Due to Asthma</title>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Days/Subject/Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.36"/>
                    <measurement group_id="O2" value="3.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Unscheduled Physician Office Visits for Respiratory Symptoms</title>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Unscheduled Physician Office Visits for Respiratory Symptoms</title>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Events/Subject/Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.05"/>
                    <measurement group_id="O2" value="0.36" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Emergency Room Visits for Respiratory Symptoms</title>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room Visits for Respiratory Symptoms</title>
          <population>Intent-to-Treat (ITT) population. Consists of all randomized subjects who were administered at least one bronchoscopy.</population>
          <units>Events/Subject/Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.03"/>
                    <measurement group_id="O2" value="0.43" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospitalizations for Respiratory Symptoms</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alair</title>
            <description>Alair treatment plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham bronchoscopy plus conventional therapy with inhaled corticosteroids and long acting β2-agonists.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations for Respiratory Symptoms</title>
          <units>Events/Subject/Year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Rates in &quot;Other Adverse Events&quot; include Serious Adverse Events. Two subjects in the BT group did not complete the 6-week visit and were classified as having missed visits. These subjects were later classified as lost to follow-up or withdrawn. Conservatively, the lowest denominator (187 instead of 189) to estimate post-treatment risk has been used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alair (Treatment Period)</title>
          <description>Day of first bronchoscopy session until 6 weeks after the last bronchoscopy session. Airways treated with the Alair System.</description>
        </group>
        <group group_id="E2">
          <title>Sham (Treatment Period)</title>
          <description>Day of first bronchoscopy session until 6 weeks after the last bronchoscopy session. Sham treatment.</description>
        </group>
        <group group_id="E3">
          <title>Alair (Post-Treatment Period)</title>
          <description>Six weeks after the last bronchoscopy session until 12 Months. Airways treated with the Alair System.</description>
        </group>
        <group group_id="E4">
          <title>Sham (Post-Treatment Period)</title>
          <description>Six weeks after the last bronchoscopy session until 12 Months. Sham treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced Expiratory Volume Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis Pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer Stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma (Multiple Symptoms)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Foreign Body Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haematoma Evacuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Asthma (Multiple Symptoms)</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Narinder S Shargill, PhD</name_or_title>
      <organization>Asthmatx, Inc.</organization>
      <phone>408-419-0100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

